News >

NICE Recommends Atezolizumab Combo in Frontline TNBC

Gina Columbus @ginacolumbusonc
Published: Friday, May 22, 2020

breast cancer
The UK's National Institute for Health and Care Excellence (NICE) has recommended the combination of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) as a treatment option for patients with unresectable, locally advanced, or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 at a level of 1% or more and have not had prior chemotherapy for metastatic disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication